Related Experiment Video
Updated: Feb 1, 2026
A Protocol for Computer-Based Protein Structure and Function Prediction
Published on: November 3, 2011
Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site
Yangguang Liu1,2, Meng Wu1,2, Tianqi Wang2
1Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China.
Abstract:
Androgen receptor (AR) plays a critical role in the development and progression of prostate cancer (PCa). Current antiandrogen therapies induce resistant mutations at the hormone binding pocket (HBP) that convert the activity of these agents from antagonist to agonist. Thus, there is a high unmet medical need for the development of novel antiandrogens which circumvent mutation-based resistance. Herein, through the analysis of AR structures with ligands binding to the activation function-2 (AF2) site, we built a combined pharmacophore model. In silico screening and the subsequent biological evaluation lead to the discovery of the novel lead compound IMB-A6 that binds to the AF2 site, which inhibits the activity of either wild-type (WT) or resistance mutated ARs. Our work demonstrates structure-based drug design is an efficient strategy to discover new antiandrogens, and provides a new class of small molecular antiandrogens for the development of novel treatment agents against PCa.
Insights
Researchers discovered a new antiandrogen, IMB-A6, that targets the androgen receptor (AR) activation function-2 site. This novel compound effectively inhibits both wild-type and mutated ARs, offering a promising strategy against resistant prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Androgen receptor (AR) is crucial in prostate cancer (PCa) development and progression.
- Current antiandrogen therapies often lead to resistance through mutations in the AR hormone binding pocket (HBP).
- There is a significant need for novel antiandrogens that overcome mutation-based resistance.
Purpose of the Study:
- To discover novel antiandrogens that circumvent mutation-based resistance in prostate cancer.
- To identify compounds targeting the AR activation function-2 (AF2) site.
Main Methods:
- Analysis of AR structures with ligands bound to the AF2 site.
- Development of a combined pharmacophore model.
- In silico screening and subsequent biological evaluation of lead compounds.
Main Results:
- Discovery of a novel lead compound, IMB-A6.
- IMB-A6 binds to the AF2 site of the androgen receptor.
- IMB-A6 inhibits the activity of both wild-type (WT) and resistance-mutated ARs.
Conclusions:
- Structure-based drug design is an effective strategy for discovering new antiandrogens.
- IMB-A6 represents a new class of small molecular antiandrogens.
- This discovery provides potential new treatment agents against prostate cancer.
Related Concept Videos
01:56Structural Protein Function
Collagen, the most abundant protein in mammals, is found throughout the body. In connective tissue, such as skin, ligaments, and tendons, it provides tensile strength and elasticity. In bones and teeth, it mineralizes to...
01:56Structural Protein Function
01:58Fruit Development, Structure, and Function
01:29Structure and Function of Erythrocytes
The erythrocyte plasma membrane is associated with proteins such as spectrin, which forms a flexible cytoplasmic meshwork. This meshwork allows erythrocytes to twist, turn, become cup-shaped, and regain their biconcave shape as they pass through narrow capillaries. Additionally, erythrocytes can form...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
01:21Structure and Function of Leukocytes
White blood cells protect the body...